Immune checkpoint inhibitors for first‐line treatment of advanced non‐small‐cell lung cancer: A systematic review and network meta‐analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Immune checkpoint inhibitors for first‐line treatment of advanced non‐small‐cell lung cancer: A systematic review and network meta‐analysis

Published:2021-09-20 Issue:21 Volume:12 Page:2873-2885
ISSN:1759-7706
Container-title:Thoracic Cancer
language:en
Short-container-title:Thorac Cancer

Author:

Peng Tzu‐Rong¹^ORCID,Lin Hung‐Hong²,Tsai Fang‐Pei¹,Wu Ta‐Wei¹³

Affiliation:

1. Department of Pharmacy Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation New Taipei City Taiwan

2. Department of Pharmacy Chia‐Nan University of Pharmacy and Science Tainan Taiwan

3. School of Pharmacy, College of Pharmacy Taipei Medical University Taipei City Taiwan

Funder

Buddhist Tzu Chi Medical Foundation

Taipei Tzu Chi Hospital

Publisher

Wiley

Subject

Pulmonary and Respiratory Medicine,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/1759-7714.14148

Reference38 articles.

1. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)

2. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries

3. Global cancer statistics, 2012

4. Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship

5. Adjuvant chemotherapy in non‐small cell lung cancer: state‐of‐the‐art;Artal Cortés Á;Transl Lung Cancer Res,2015

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of efficacy and safety of PD-1/PD-L1 combination therapy in first-line treatment of advanced NSCLC: an updated systematic review and network meta-analysis;Clinical and Translational Oncology;2024-04-16

2. Comparison of the Efficacy and Safety of Perioperative Immunochemotherapeutic Strategies for Resectable Non-small Cell Lung Cancer: a Systematic Review and Network Meta-analysis;Clinical Oncology;2024-02

3. Microphysiological systems for solid tumor immunotherapy: opportunities and challenges;Microsystems & Nanoengineering;2023-12-15

4. Global Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2;Cancers;2023-07-22

5. Treatment-free survival after discontinuation of immune checkpoint inhibitors in mNSCLC: a systematic review and meta-analysis;Frontiers in Immunology;2023-07-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3